Pro-Dex, Inc. (PDEX) AI Stock Analysis

Pro-Dex, Inc., headquartered in Irvine, California, specializes in the design, development, manufacturing, and global distribution of powered surgical instruments for medical device original equipment manufacturers. Founded in 1978, the company serves the orthopedic, thoracic, and craniomaxillofacial markets with autoclavable, battery-powered, and electric surgical drivers and shavers. Pro-Dex also delivers engineering, quality, and regulatory consulting services across product lifecycles. Additionally, the company manufactures and supplies rotary air motors to various industries, supporting medical OEMs in enhancing surgical outcomes while maintaining safety and efficiency standards.

Pro-Dex expanded revenue from $42.0M in FY2022 to $77.5M in FY2026, reflecting a five-year revenue compound annual growth rate of 13.0%. Net income rose from $4.6M in FY2022 to $13.7M in FY2026, accompanied by an increase in diluted earnings per share from $1.04 to $4.13. Gross margin strengthened from 27.0% in FY2024 to 31.4% in FY2026, while operating margin rose to 16.8%. In the latest quarter ended June 30, 2026, quarterly revenue grew 16.6% year-over-year, and quarterly earnings grew 143.4%.

As of June 30, 2026, Pro-Dex held $9.3M in cash and short-term investments alongside $18.1M in total debt, resulting in net debt of $8.8M. Total assets stood at $74.5M against shareholders' equity of $47.6M, yielding a debt-to-equity ratio of 0.38 and a current ratio of 4.10. Operating cash flow reached $7.2M in FY2026, supporting $6.8M in free cash flow after $483,000 in capital expenditures. Cash allocation included $3.4M in share buybacks, contributing to an 11.9% reduction in share count over five years.

At $58.26, Pro-Dex carries a market capitalization of $188.4M and an enterprise value of $241.6M. The stock trades at a trailing price-to-earnings ratio of 14.1x, below the 24.6x median of its US-listed Healthcare peers, though its forward price-to-earnings ratio of 23.4x sits above the peer median of 17.3x. Its enterprise value-to-revenue multiple of 3.1x aligns against a price-to-sales multiple of 2.4x, which compares to the peer median of 4.1x. Over the past year, the stock returned 143.7%, outperforming the 16.8% return of the S&P 500.

One analyst covers Pro-Dex with a Strong Buy rating and a mean price target of $74.00, representing an upside of 27.0% from the last close of $58.26. The analyst projects FY2027 revenue of $82.7M and an earnings per share decline of 25.0% to $3.09. For FY2028, revenue is forecast to grow 5.0% to $86.8M with earnings per share rising 8.7% to $3.36. The company beat earnings estimates in each of the last four quarters, with its next earnings report scheduled for October 29, 2026.

This page is an AI-written research summary of Pro-Dex, Inc. (PDEX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PDEX income statement, PDEX balance sheet, PDEX key metrics, PDEX analyst forecast, PDEX chart. See the PDEX stock overview for the latest quote and news.